Linked Life Data

3534967

Source:http://linkedlifedata.com/resource/pubmed/id/3534967

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1986-11-24
pubmed:abstractText
Neuroblastoma is a radiosensitive neoplasm for which total body irradiation (TBI) is presently under clinical consideration. Collated data on the radiobiology of human neuroblastoma cells in vitro (11 cell lines derived from seven patients) indicates moderate cellular radiosensitivity and low capacity for accumulation of sublethal damage (median survival curve parameters: Do = 104 cGy, Dq = 32 cGy, n = 1.36). Mathematical studies incorporating these parameters suggest that low dose fractionated TBI is unlikely to achieve significant levels of tumour cell kill. When high dose TBI is used in conjunction with bone marrow rescue a tumour "log cell kill" of 4-5 should be achievable. This effect would be additional to that achieved by chemotherapy. The optimum schedule for exploitation of radiobiological differences between neuroblastoma cells and the dose-limiting normal tissues has a hyperfractionated structure. Twice-daily treatments with fraction sizes in the region 120-150 cGy seems appropriate. Single dose treatments at high dose rate are contraindicated. Fractionated TBI with bone marrow rescue may be curative for some patients in clinical remission who are presently destined to relapse.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0167-8140
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
317-26
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Radiobiological considerations in the treatment of neuroblastoma by total body irradiation.
pubmed:publicationType
Journal Article